Core Viewpoint - Target (TGT) is expected to report quarterly earnings of $2.17 per share, reflecting a 10% decline year-over-year, with revenues forecasted at $30.54 billion, a decrease of 1.2% compared to the previous year [1]. Financial Estimates - Analysts predict 'Net Sales- Merchandise sales- Beauty & household essentials' to reach $3.36 billion, indicating a significant decline of 59.1% from the same quarter last year [4]. - The estimated 'Net Sales- Merchandise sales- Food & beverage' is projected at $6.47 billion, showing a slight decrease of 0.8% year-over-year [4]. - 'Net Sales- Merchandise sales- Hardlines' is expected to be $5.99 billion, reflecting a year-over-year decline of 2.5% [5]. - 'Net Sales- Merchandise sales- Other' is anticipated to reach $92.96 million, indicating a decrease of 4.2% from the prior-year quarter [5]. Store and Retail Metrics - The average prediction for 'Number of stores - Total' is 2,002, up from 1,978 reported in the same quarter last year [6]. - The consensus estimate for 'Retail Square Feet - Total' stands at 251 million square feet, compared to 248 million square feet a year ago [6]. - 'Retail Square Feet - 50,000 to 169,999 sq. ft' is expected to be 198 million square feet, an increase from 195 million square feet reported last year [7]. - 'Digitally Originated Comparable Sales Change' is projected to be 4.2%, down from 8.7% in the previous year [7]. - 'Retail Square Feet - 170,000 or more sq. ft' is expected to remain at 49 million square feet, consistent with last year's figure [8]. - The estimate for 'Number of stores - 49,999 or less sq. ft' is projected at 147, compared to 146 last year [8]. - The consensus for 'Number of stores - 50,000 to 169,999 sq. ft' is 1,580, up from 1,559 reported last year [9]. - 'Number of stores - 170,000 or more sq. ft' is expected to remain at 273, unchanged from the previous year [9]. Stock Performance - Target shares have shown a return of +14.5% over the past month, outperforming the Zacks S&P 500 composite, which increased by +0.6% [9].

分组1 - Maravai LifeSciences Holdings, Inc. reported a quarterly loss of $0.04 per share, better than the Zacks Consensus Estimate of a loss of $0.07, and improved from a loss of $0.06 per share a year ago, resulting in an earnings surprise of +40.03% [1] - The company posted revenues of $49.87 million for the quarter ended December 2025, surpassing the Zacks Consensus Estimate by 1.21%, but down from $56.56 million in the same quarter last year [2] - Maravai LifeSciences shares have underperformed the market, losing about 4% since the beginning of the year compared to the S&P 500's gain of 0.7% [3] 分组2 - The current consensus EPS estimate for the coming quarter is -$0.05 on revenues of $57.61 million, and for the current fiscal year, it is -$0.22 on revenues of $210.65 million [7] - The Zacks Industry Rank for Medical - Products is in the bottom 44% of over 250 Zacks industries, indicating that the industry outlook can significantly impact stock performance [8]

Core Viewpoint - Apollo Global Management Inc. is expected to report quarterly earnings of $2.03 per share, reflecting an 8.6% decline year-over-year, while revenues are forecasted to increase by 24.8% to $1.19 billion [1]. Earnings Estimates - Over the past 30 days, the consensus EPS estimate has been adjusted downward by 1%, indicating a reassessment by analysts [2]. - Changes in earnings estimates are crucial for predicting investor reactions to the stock, with empirical studies showing a strong relationship between earnings estimate revisions and short-term stock performance [3]. Key Metrics Forecast - Total Assets Under Management are expected to reach $934 billion, up from $750 billion a year ago [5]. - Segment Income from Asset Management related to Fee Related Earnings from Management fees is projected at $918.43 million, compared to $742 million in the same quarter last year [5]. - Segment Income from Asset Management related to Fee Related Earnings from Capital solutions fees and other is expected to be $195.97 million, up from $160 million year-over-year [6]. - Fee-related performance fees are estimated at $73.93 million, compared to $53 million last year [6]. - Segment Income from Retirement Services related to Spread Related Earnings from Alternative net investment income is forecasted at $331.50 million, up from $269 million a year ago [7]. - Segment Income from Principal Investing related to Realized investment income is estimated at $17.57 million, down from $32 million last year [7]. - Segment Income from Principal Investing related to Realized performance fees is projected at $280.95 million, down from $321 million year-over-year [8]. - Segment Income from Retirement Services related to Spread Related Earnings from Fixed income and other net investment income is expected to reach $3.48 billion, compared to $2.91 billion last year [9]. - Strategic capital management fees are projected at $35.24 million, up from $29 million last year [10]. - Segment Income from Principal Investing is estimated at $71.08 million, down from $139 million last year [10]. - Combined Segment Income from Retirement Services related to Spread Related Earnings is expected to be $846.85 million, slightly up from $841 million last year [11]. - Segment Income from Asset Management related to Fee Related Earnings is projected at $669.55 million, compared to $554 million a year ago [12]. Stock Performance - Apollo Global Management shares have decreased by 16.9% over the past month, contrasting with a 0.9% increase in the Zacks S&P 500 composite [12].

Core Insights - The article discusses the latest trends and developments in the investment banking sector, highlighting key financial metrics and market movements. Group 1: Industry Trends - Investment banking has seen a significant increase in M&A activity, with a reported growth of 25% year-over-year in deal volume [1] - The sector is experiencing heightened competition, particularly among boutique firms that are gaining market share from traditional banks [1] Group 2: Company Performance - Major investment banks reported a collective revenue increase of 15% in the last quarter, driven by strong advisory fees and trading revenues [1] - Specific firms have outperformed the market, with one leading bank achieving a 30% increase in net income compared to the previous year [1]

Core Insights - Eli Lilly has been a prominent player in the pharmaceutical sector but has faced challenges in 2025, with expectations for a turnaround in Q3 results [1] Group 1: Wall Street Expectations - Analysts predict Q3 revenue for Eli Lilly to be approximately $16 billion, reflecting a year-over-year increase of 40.5% [2] - The average earnings per share (EPS) estimate for Q3 is $5.92, with a range from a pessimistic $5.49 to an optimistic $7.21, indicating significant growth from the $1.18 EPS reported in Q3 2024 [3] Group 2: Growth Drivers - Key products driving growth include the Type 2 diabetes drug Mounjaro and the obesity drug Zepbound, which together account for around 55% of total revenue [4] Group 3: Stock Performance Trends - Historical performance shows that even when Eli Lilly beats analyst estimates, stock reactions can be unpredictable, as seen in the last four quarters where the stock did not consistently respond as expected [5][6] - Despite beating EPS estimates in Q4 2024, the stock initially gained but quickly lost those gains, while a miss in Q1 2025 did not lead to a decline in stock price [6] Group 4: Long-term Perspective - Analysts suggest maintaining a long-term investment perspective with Eli Lilly, as short-term stock movements may not align with earnings performance [7]